In its Q4 earnings call to investors on February 25, vaccine developer Vaxcyte expressed optimism about its VAX-31 invasive pneumococcal disease (IPD) vaccine program and discussed the company’s ...

Japan-based pharmaceutical company Kyowa said it is planning to buy land in the Helix Innovation Park in Sanford, North Carolina to build a manufacturing facility to support the production and supply ...

At the JP Morgan Healthcare Conference, while addressing the state of the company in 2025, experts from Gilead Sciences touted the company’s manufacturing infrastructure as one of its key advantages ...

Announced in 2021, the facility, named Modulus, is expected to be fully operational by 2026 and will create about 200 jobs locally. Modulus is Sanofi’s first "EVolutive vaccine facility (EVF)" outside ...

The firms will co-commercialize the products globally, except for MK-6070 in Japan where Merck (known as MSD outside of the US and Canada) will retain the exclusive rights. Merck will also be solely ...

Isolere Bio is on a mission to transform biomanufacturing and tackle the traditional limitations in downstream processing with its novel IsoTag reagents. This first-of-its-kind technology is based on ...

Founded in the middle of 2002, BPI published its first issue in January of 2003. Our 20th-anniversary issue thus takes the form of a state-of-the-early-21st-century industry report. Assembling this ...

In 2021, Fujifilm began constructing a biomanufacturing site in Holly Springs, North Carolina at a cost of ¥200 billion (then $2 billion, now $1.3 billion) for its contract development manufacturing ...

Market experts recommend automated filling systems for drug developers seeking to reach the next level in drug-substance management. Many companies are starting automation initiatives, which suggests ...

Industry will see mid-teens grams/L of product within five years but downstream processes are the big ‘virgin territory’ for further productivity gains, says Avantor’s Ger Brophy. In the aftermath of ...

Biologics have revolutionized the medical landscape with their targeted mechanisms of action and potential for treating a wide array of indications. As the global population grapples with an ...

Sanofi will build a €1 billion ($1.1 billion) mAb production facility in Vitry-sur-Seine, while it invests €100 million to bolster capacity at its Le Trait site in Normandy and invests €10 million at ...